<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191864</url>
  </required_header>
  <id_info>
    <org_study_id>SP-1011-002</org_study_id>
    <secondary_id>2016-004749-10</secondary_id>
    <nct_id>NCT03191864</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)</brief_title>
  <acronym>FLUTE</acronym>
  <official_title>FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adare Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adare Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by
      eosinophilic infiltration and gastrointestinal symptoms. Swallowed, topically acting
      corticosteroids, such as fluticasone, appear to be effective in resolving acute clinical and
      pathological features of EoE.

      APT-1011 is an orally disintegrating tablet (ODT) formulation of fluticasone propionate. This
      study is designed to compare the efficacy and safety of APT-1011 with placebo in adults with
      EoE for an initial 12-week treatment period, followed by an additional 40-week maintenance
      treatment phase. Histologic response, pharmacokinetics, and dysphagia will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FLUTE is a phase 2b randomized, double-blind, placebo-controlled dose-ranging clinical trial
      of APT-1011 versus placebo in 100 adult subjects (≥18 years of age) diagnosed with EoE.
      Efficacy (including histologic, endoscopic, and symptomatic response), safety, and PK of
      APT-1011 will be examined. Participants will be given an electronic diary to record symptoms
      and medication intake daily.

      FLUTE will be conducted in several parts (Screening [4 weeks], followed by a 4-week Baseline
      Symptom Assessment, and 2 treatment parts [Part 1: 14-week Induction and Part 2: 38-week
      Maintenance]), with a follow-up visit to occur 2 weeks after the final dose of study drug.

      In Part 1 of the study, 100 subjects will be randomized 1:1:1:1:1 to receive placebo or one
      of 4 active doses of APT-1011. All subjects will receive one tablet 30 minutes after
      breakfast and one tablet at bedtime (HS). The dosing groups include: 1.5 mg HS APT-1011, 1.5
      mg twice daily (BID) (total daily dose of 3 mg) APT-1011, 3 mg HS APT-1011, and 3 mg BID
      (total daily dose of 6 mg) APT-1011, and placebo BID.

      In Part 2, all subjects classified as histologic responders at Week 12 will continue to be
      treated according to the dosing group to which they were randomized, and non-responders will
      receive single-blind 3 mg BID. All subjects who are histologic non-responders at Week 26 will
      stop treatment at Week 28 and enter the 2-week follow-up and exit the study. Histologic
      responders at Week 26 will continue on the same dose until end-of-study at Week 52.

      Subjects will complete a follow-up visit 2 weeks after the final dose of study drug. All
      subjects must have a final EGD within 3 weeks prior to completing the Follow-up Visit unless
      the subject withdraws consent or has a contraindication to EGD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Histological response</measure>
    <time_frame>Week 12</time_frame>
    <description>Histology (eosinophils per high power field [HPF]): percentage of subjects with ≤6 PEAK eosinophils/HPF after assessing at least 5-6 biopsies from the proximal and distal esophagus (~3 each) where the HPF area is 235 square microns (40 magnification lens with a 22 mm ocular).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EoE sustained response</measure>
    <time_frame>Week 12, Week 26, and Week 52</time_frame>
    <description>Percentage of subjects who met the primary endpoint (histology) at Week 12 and maintained the primary endpoint at Week 26 and Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline EREFs at Week 12, 26, and 52</measure>
    <time_frame>Week 12, Week 26, and Week 52</time_frame>
    <description>Endoscopic changes will be assessed as per the EREFs evaluation based on the following endoscopic features: edema, rings, exudates, furrows, stricture, and several miscellaneous features (crepe paper esophagus, narrow caliber esophagus, and esophageal erosions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EoE histologic response</measure>
    <time_frame>Week 12, Week 26, and Week 52</time_frame>
    <description>Percentage of subjects with a peak eosinophils/HPF &lt;1 and &lt;15 at Week 12, 26 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Global EoE Symptom Score</measure>
    <time_frame>Week 52</time_frame>
    <description>Compared score prior to randomization to scores for 7-day recall at Week 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysphagia</measure>
    <time_frame>Week 12, Week 26 and Week 52</time_frame>
    <description>Change in the number of dysphagia episodes at baseline (14-day period prior to randomization) compared with the 14-day period prior to the time point of interest</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HPA axis suppression</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Number of subjects discontinuing due to HPA axis suppression</description>
  </other_outcome>
  <other_outcome>
    <measure>Candidiasis</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Frequency of oral and esophageal candidiasis</description>
  </other_outcome>
  <other_outcome>
    <measure>Oral clearance</measure>
    <time_frame>Week 12</time_frame>
    <description>Oral clearance (CL/F)</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>Week 12</time_frame>
    <description>Volume of distribution (V/F)</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>APT-1011 1.5 mg HS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo after breakfast, APT-1011 1.5 mg HS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APT-1011 1.5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APT-1011 3 mg HS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo after breakfast, APT-1011 3 mg HS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APT-1011 3 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APT-1011 3 mg after breakfast, APT-1011 3 mg HS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 30 minutes after breakfast and HS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APT-1011</intervention_name>
    <description>APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate</description>
    <arm_group_label>APT-1011 1.5 mg HS</arm_group_label>
    <arm_group_label>APT-1011 1.5 mg BID</arm_group_label>
    <arm_group_label>APT-1011 3 mg HS</arm_group_label>
    <arm_group_label>APT-1011 3 mg BID</arm_group_label>
    <other_name>Fluticasone propionate ODT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.</description>
    <arm_group_label>APT-1011 1.5 mg HS</arm_group_label>
    <arm_group_label>APT-1011 3 mg HS</arm_group_label>
    <arm_group_label>Placebo BID</arm_group_label>
    <other_name>Matching placebo dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between ≥18 and ≤75 years of age at the time of informed consent

          -  Signed informed consent

          -  Evidence of EoE defined by ≥15 peak eosinophils per HPF as measured from proximal and
             distal biopsies

          -  Subject-reported history of ≥3 episodes of dysphagia in the 7 days prior to Screening

          -  7-day Global EoE Symptom Score &gt;3 at baseline and at screening

          -  Willing and able to adhere to study-related treatment regimens, procedures, and visit
             schedule

        Exclusion Criteria:

          -  Have known contraindication, hypersensitivity, or intolerance to corticosteroids;

          -  Have any physical, mental, or social condition or history of illness or laboratory
             abnormality that in the Investigator's judgment might interfere with study procedures
             or the ability of the subject to adhere to and complete the study;

          -  Presence of oral or esophageal mucosal infection of any type;

          -  Have any mouth or dental condition that prevents normal eating;

          -  Have any condition affecting the esophageal mucosa or altering esophageal motility
             other than EoE;

          -  Use of systemic corticosteroids within 60 days prior to Screening, use of
             inhaled/swallowed corticosteroids within 30 days prior to Screening, or extended use
             of high-potency dermal topical corticosteroids within 30 days prior to Screening;

          -  Initiation of an elimination diet or elemental diet within 30 days before Screening
             (diet must remain stable after signing ICF);

          -  Morning serum cortisol level ≤5 μg/dL (138 nmol/L);

          -  Use of biologic immunomodulators in the 24 weeks prior to Screening;

          -  Use of calcineurin inhibitors or purine analogues, or potent cytochrome P450 (CYP) 3A4
             inhibitors in the 12 weeks prior to Screening;

          -  Have a contraindication to or factors that substantially increase the risk of EGD or
             esophageal biopsy or have narrowing of the esophagus that precludes EGD with a
             standard 9 mm endoscope;

          -  Have a history of an esophageal stricture requiring dilatation within the previous 12
             weeks prior to Screening;

          -  Have initiated, discontinued or changed dosage regimen of PPIs, H2 antagonists,
             antacids or antihistamines for any condition such as GERD or allergic rhinitis within
             4 weeks prior to qualifying endoscopy. These drugs must remain constant throughout the
             study.

          -  A serum cortisol level &lt;18 μg/dL (497 nmol/L) at 60 minutes with adrenocorticotropic
             hormone (ACTH) stimulation test using 250 μg cosyntropin (i.e., a positive result on
             the ACTH stimulation test).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian A Meltzer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Adare Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian A Meltzer, MD</last_name>
    <phone>(609) 450-1312</phone>
    <phone_ext>4033</phone_ext>
    <email>Brian.Meltzer@adarepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Brooks, PhD</last_name>
    <phone>(609) 450-1312</phone>
    <phone_ext>4026</phone_ext>
    <email>karen.brooks@adarepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Del Sol Research Management, LLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tushar Gohel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Gottlieb</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Gastroenterology, P.A.</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <zip>72120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Wofford, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hessam Aazami, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020-4124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Lipkis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Center for Digestive Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Davidson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taddese Desta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bennett, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Access Research LLC</name>
      <address>
        <city>San Pablo</city>
        <state>California</state>
        <zip>94806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kogan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Nadeau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Network</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mae Tighe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Connecticut, LLC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Feuerstadt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials - Parent</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rizwana Thanawala, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research, LLC</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Hellstern, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Schneider, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Gastroenterology</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453-3767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamran Ayub, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rockford Gastroenterology Associates, Ltd.</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center, Digestive Health</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Welton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, Inc.</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarence Dunn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group, PC</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mukul Khandelwal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center, Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111-1526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Leung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377-3600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Tang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metro Health</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Coates, DO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Center for Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Dimitroff</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Dellon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Johnston, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PhysiqueMed Clinical Trials</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyothi Mann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Carolinas, PLC</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timorthy Barker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina's GI Research, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhash Gumber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Barish, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vineet Korrapati, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Health Physicians Office</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Kushner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sridhar Guduri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Specialists, Inc.</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry A Bookman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unity Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Holbrook</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jackson Siegelbaum Gastroenterology</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Jackson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Falk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates, Ltd.</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis La Luna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rapid City Medical Center, LLP</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Jones, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Gastroenterology</name>
      <address>
        <city>Union City</city>
        <state>Tennessee</state>
        <zip>38261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kofi Nuako, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates, LLC - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nomita Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates, LLC</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Blahey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DHAT Research Institute</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Sarles, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wichita Falls Gastroenterology Associates</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Wilson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lowe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Access Research LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Joseph, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Verity Research Inc</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Mirkin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists, Ltd.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Wootton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Exemplar Research Inc</name>
      <address>
        <city>Elkins</city>
        <state>West Virginia</state>
        <zip>26241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitesh Ratnakar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joris Arts</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny De Looze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Van Moerkercke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Tack</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>(G.I.R.I.) GI Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hin Hin Ko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viable Clinical Research</name>
      <address>
        <city>Bridgewater</city>
        <state>Nova Scotia</state>
        <zip>B4V 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hughie Fraser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viable Clinical Research</name>
      <address>
        <city>Lindsay</city>
        <state>Ontario</state>
        <zip>K9V 5G6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Chan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vipul Jairath</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taunton Surgical Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Green</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Tomelloso</name>
      <address>
        <city>Tomelloso</city>
        <state>Ciudad Real</state>
        <zip>13700</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Lucendo Villarin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Guarner Argente</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danila Guagnozzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilio Santander Vaquero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeles Pizarro Moreno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pilar Mas Mercader</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Sopeña Biarge</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Alcedo Gonzalez</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagitis</keyword>
  <keyword>Eosinophilic Esophagitis</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Dysphagia</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Esophageal Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Orally Disintegrating Tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

